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Context: Polycystic ovary syndrome (PCOS) is frequently associated with insulin resistance.
Objective: The aimof the studywas to investigate a putative role of the adipokines retinol-binding
protein 4 (RBP4), adiponectin, and visfatin in a cohort of patients with PCOS and their response to
treatment with pioglitazone.
Design and Setting: We conducted a randomized, controlled, double-blind study at a tertiary
referral center.
Patients and Interventions: Forty premenopausal women with PCOS were allocated to receive
treatment with either pioglitazone (30 mg/d) or a placebo for a period of 3 months.
Main Outcome Measures: Serum concentrations of RBP4, adiponectin, and visfatin were deter-
mined along with metabolic and hormonal parameters before and after treatment.
Results: Serumadiponectin concentrationswerehigherafter treatmentwithpioglitazone (P0.003),
whereas RBP4 levels tended to decrease (P 0.06), and visfatin concentrations remained unchanged.
We found RBP4 serum concentrations at baseline to be positively correlated with serum levels of
testosterone (R  0.446; P  0.005), 17-OH progesterone (R  0.345, P  0.037), and dehydroepi-
androsterone sulfate (R  0.347; P  0.041). However, these correlations were abolished after
treatment with pioglitazone. Patients with high RBP4 levels had significantly higher hirsutism
scores (P  0.038 before and P  0.034 after treatment). In contrast, serum adiponectin concen-
trations were related to parameters of impaired glucose metabolism, and no significant associa-
tions were detected for visfatin.
Conclusions: Our results suggest that RBP4 may contribute to endocrine changes and to the phe-
notypic manifestation of patients with PCOS because higher RBP4 concentrations are associated
with higher androgen levels and higher clinical hirsutism scores independently of pioglitazone
treatment. The molecular involvement of RBP4 in human steroid metabolism requires further
clarification. (J Clin Endocrinol Metab 94: 1229–1235, 2009)
It iswell acknowledged that both excessive leanness andobesityadversely affect female reproductive function (1). Over-
weight has become increasingly common and is associated with
the polycystic ovary syndrome (PCOS) affecting approximately
6% of women at a reproductive age (2, 3). PCOS is a heteroge-
neous condition characterized mainly by hyperandrogenism,
chronic anovulation, and infertility (4, 5). Although the precise
pathogenesis of PCOS remains uncertain, a close link to insulin
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resistance (IR) and consecutive hyperinsulinemia, impaired glu-
cose tolerance, type 2 diabetes mellitus, atherogenic dyslipide-
mia, and visceral obesity has been well established (6). Like
PCOS, IR is also associatedwith both obesity and lipodystrophy
(7, 8). PCOS and obesity have a synergistic deleterious effect on
glucose tolerance, but IR is found in nonobese PCOS patients as
well, thereby contributing to the high cardiovascular risk known
to occur in these women (9, 10).
More recently, several studies have demonstrated that effec-
tive reduction of IR induces regular menstrual cycles and im-
proves fertility in patients with PCOS (11). This has been shown
for administration of diazoxide (12), metformin (13, 14), and
more recently also thiazolidinediones (15, 16). Pioglitazone is a
thiazolidinedionederivative that hasbeenapproved for the treat-
ment of type 2 diabetes and appears to have both antiinflam-
matory and antiatherosclerotic properties (17).
Excess visceral adipose tissue is thought to play a key role in
mediating metabolic disturbances characteristic of IR (18). Sev-
eral adipose tissue-derivedhormones, namedadipokines, suchas
leptin, adiponectin, visfatin, retinol-bindingprotein4 (RBP4), or
resistin, have been shown to facilitate changes in carbohydrate
and lipidmetabolism, thereby being involved in the pathogenesis
of IR (19, 20). Serumconcentrations of leptin,RBP4, and resistin
are increased in insulin-resistant states, whereas inadequately
low concentrations of adiponectin are characteristic of IR. The
relationship of visfatin to IR remains controversial (20). It was
therefore hypothesized thatRBP4, adiponectin, and visfatinmay
be involved in the pathogenesis of PCOS. Hence, we aimed to
investigate the effect of thiazolidinedione treatment on serum
RBP4, adiponectin, and visfatin levels and potential relation-
ships between these adipokines and parameters of glucose me-
tabolism as well as endocrine changes in patients with PCOS. At
present, no studydealingwith PCOSwasperformed inwhich the
role of those novel factors has been studied in a prospective
randomized setting.
Subjects and Methods
Subjects and study protocol
Forty patients were included in the study, and the diagnosis of PCOS
was established as described (15). Statistical power analysis was per-
formed for the initial study assessing the metabolic and hormonal ther-
apeutic properties of pioglitazone in patients with the PCOS, and there-
fore no additional statistical power calculation was performed. The
present study was a follow-up investigation on that study. PCOS was
diagnosed by the presence of 1) long-standing ovulatory dysfunction
(oligo- or amenorrhea); 2) hirsutism (Ferriman-Gallwey score 7)
and/or circulating serum total testosterone greater than 2.5 nmol/liter
and SHBG concentrations less than 50 nmol/liter; and 3) exclusion of
other endocrine disorders, such as thyroidal dysfunction, adrenal dis-
eases, and hyperprolactinemia. Other exclusion criteria were desire for
pregnancy or existing pregnancy, basal FSH concentration greater than
20 IU/liter, diabetes mellitus, past hysterectomy, intake of medication
knownor suspected to affect reproductive ormetabolic function, history
of liver disease and/or alcohol abuse, elevated liver enzymes, or severe
uncontrolled illness. All subjects showed a polycystic appearance of the
ovaries on transvaginal sonography. All potentially fertile patients were
asked to use barrier methods of contraception during the entire study
period. After having signed written informed consent, patients were re-
quested to adhere to a written list of recommendations concerning a
healthy diet andphysical activity forweightmaintenance during a period
of 4 wk while knowingly receiving placebo (run-in phase). Thereafter,
randomization was performed, and treatment with either 30 mg piogli-
tazone or placebo (identical tablets, taken once daily) was begun. Pa-
tients and physicians were blinded to the applied treatment. Every other
week, each patient had an appointment with the treating physician;
vital signs and body measurements [body mass index (BMI)] were
determined, and serum was taken for the determination of proges-
terone concentrations. At each visit, compliance with the medication
was checked by pill count. The study protocol was approved by the
regional ethics committee.
Hormonal parameters
Venous blood samples were obtained after an overnight fast in cyclic
women in the follicular phase (d 3–8) of the cycle, at the end of the run-in
phase, and at the end of the treatment phase for measurement of serum
concentration of total testosterone, SHBG, dehydroepiandrosterone sul-
fate (DHEAS), FSH, LH, progesterone, low-density lipoprotein, high-
density lipoprotein, cholesterol, triglycerides, and liver enzymes. LHRH
testwithmeasurement of concentrations ofLHandFSHafter iv injection
of 100 g LHRH (Ferring, Wallisellen, Switzerland) was performed to
assess pituitary function, and an oral glucose tolerance test (OGTT) was
conducted to assess glucose tolerance, insulin sensitivity, and-cell func-
tion [homeostasis model assessment-insulin resistance (HOMA-IR)].
Whole body insulin sensitivity was defined by the Matsuda index cal-
culated as: 10,000/square root of [fasting glucose  fasting insulin] 
[mean glucose  mean insulin during OGTT]. In addition, insulin re-
sistance was calculated using HOMA-IR: fasting insulin (mol/
liter)fasting glucose (mmol/dl)/22.5. The area under the curve (AUC) of
insulin was calculated by integrating insulin levels obtained during
OGGT. Serum samples were immediately stored at70 C, and all mea-
surements were performed after completion of the study (Laboratories
Scho¨nenbuch, Allschwil, Switzerland); serum 17-OH progesterone (ref-
erence range, follicular phase, 0.6–4.7 nmol/liter), LH (reference range,
follicular phase, 0.4–12.6 IU/liter; Second NIBSC 80/552), FSH [refer-
ence range, follicular phase, 3.5–12.5 IU/liter; Second International Ref-
erence Preparation (World Health Organization) 78/549], testosterone
(reference range, 2.7–2.9 nmol/liter), DHEAS (reference range, 2.7–9.2
mol/liter), and insulin [reference range, 21–118 pmol/liter; First Inter-
national Reference Preparation (World Health Organization) 66/304]
were measured by electrochemiluminescence immunoassays (Roche,
Rotkreuz, Switzerland). Liver enzymes, glucose, and lipids were mea-
sured using enzymatic methods (Roche Hitachi). The free androgen in-
dex (FAI) was calculated as: testosterone (nmol/liter)  100/SHBG
(nmol/liter). The occurrence of ovulation was assessed for each patient
by serial measurement of serum progesterone in combination with self-
reported menstruation. Ovulation was defined as progesterone levels
exceeding 9 nmol/liter with consecutive menstruation after 2 wk as an
indicator of ovulation. The inaccuracy of the test systems (interassay
coefficient of variation) was on average less than 5%.
Adipokine measurement
Sera of women with PCOS treated according to the study protocol
were analyzed. Serum RBP4 was measured by an ELISA (Immundiag-
nostic, Bensheim, Germany) that was used in groups 1 and 3 of the
original studies showing an association of RBP4 with IR (21). The con-
centrations of adiponectin and visfatin in the serumweremeasured using
the Human Adiponectin/Acrp30 immunoassay (R&D Systems GmbH,
Wiesbaden- Nordenstadt, Germany) and Human Visfatin Elisa Kit
(AdipoGen, Brisbane, Australia), respectively. Intra- and interassay co-
efficients of variation of immunoassays were less than 8%. All measure-
ments were performed before and after treatment with pioglitazone.
Statistical methods
The Gaussian distribution of all parameters was confirmed by
Kolmogorov-Smirnov tests. The efficacy of treatment (placebo vs. pio-
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glitazone; within-subject effects before vs. after treatment) was com-
pared between the two study groups by ANOVA with repeated mea-
surements; ovulation rates were compared by 2 tests. Multivariate
regression analysis was performed to calculate independent associations
between variables. Paired t test was performed to compare adiponectin,
visfatin, and RBP4 concentrations before and after pioglitazone treat-
ment. Data are the mean SEM. Data analysis was performed using the
statistical software package SPSS forWindows (SPSS, Inc., Chicago, IL).
Results
Clinical, metabolic, and hormonal characteristics of the
study cohort
The characteristics of the study cohort and the effect of pio-
glitazone treatmentonhormonal andmetabolic parameters have
beenpublishedpreviously (15), and these results are summarized
in Table 1.
Thirty-five (87.5%) of the initially enrolled 40 patients com-
pleted the trial, and data were available for analyses. Treatment
with pioglitazone resulted in a decrease in both fasting serum
insulin concentrations and AUCs of serum insulin during the
OGTT (P 0.02). Consistent with these results, we observed an
increase in calculated insulin sensitivity (P0.05) andadecrease
in estimated insulin secretion (P0.02) comparedwith placebo.
Thus, the expected metabolic effects of pioglitazone treatment
were confirmed. Waist/hip ratio, hirsutism, and BMI remained
unchanged during the course of the study in both groups. In the
pioglitazone treatment group, 41.2% of the patients presented
with the laboratory and clinical signs of ovulatory menstrual
cycles (i.e. three ovulations during the study period) as compared
with 5.6% of subjects treated with placebo (P  0.02).
Adiponectin
We found that serumadiponectin concentrations increased in
response to pioglitazone treatment (P0.003; Fig. 1A),whereas
they remained unchanged in the placebo group (P 0.985; Fig.
1B). We found correlations between baseline adiponectin con-
centrations and serum triglycerides (R  0.338; P  0.05),
high-density lipoprotein cholesterol (R  0.571; P  0.001),
response to oral glucose tolerance testing (AUC; negative corre-
lation; P  0.05 at 30, 60, 90, and 120 min), and insulin sensi-
tivity index (R  0.445; P  0.009). Serum insulin concentra-
tions (AUC) during OGTT at the end of the treatment period
correlated negatively with serum adiponectin levels at 60, 90,
and 120 min (P  0.05). Serum baseline and end of treatment
glucose and insulin concentrations were found to be inversely
linked to baseline adiponectin levels (P 0.05). IR, as calculated
by HOMA-IR, was not statistically correlated with adiponectin
concentrations at baseline, butwas after treatment (R0.362;
P  0.038).
We did not observe associations between adiponectin and
steroid hormone parameters at baseline. However, although
FSH serum concentrations in response to LHRH stimulation
were not related to adiponectin levels at baseline, the response
after treatment was significantly negatively associated with adi-
ponectin levels (R 0.45; P  0.02 at 0, 20, 30, and 60 min,
respectively), reflecting the simultaneous increase of serum adi-
ponectin concentration and the improvement in LHRH reactiv-
ity in the treated group. Moreover, the increase of adiponectin
serum concentrations in response to treatment correlated with
ovulation rates (R  0.468; P  0.011).
Visfatin
We found that in both treatment groups the serum visfatin
concentrations underwent no significant changes (Fig. 1, C and
D). Although visfatin is considered to be involved in the patho-
physiology of IR, we did not observe any statistically significant
association between serum visfatin concentration andmetabolic
parameters. Furthermore, we did not detect correlations be-
TABLE 1. Clinical, metabolic, and hormonal parameters of the study cohort before and after pioglitazone treatment
Parameter
Pioglitazone (n  17) Placebo (n  18)
Before After Before After
Age (yr) 30.2  1.4 30.6  1.1
BMI (kg/m2) 29.4  1.7 30.1  1.7 27.5  1.2 27.7  1.2
Waist/hip ratio 0.9  0.1 0.8  0.0 0.9  0.0 0.8  0.0
Hirsutism (Ferriman-Gallwey score) 15.5  1.2 15.6  1.3 15.6  2.0 15.8  2.8
Fasting plasma glucose (mmol/liter) 4.8  0.1 4.8  0.1 4.8  0.1 5.0  0.1
Glucose AUC (mmol/liter  min) 789.9  53.3 694.2  42.9a 804.3  52.6 788.8  40.6
Fasting serum insulin (pmol/liter) 68.3  9.7 53.2  5.3b 47.8  4.6 62.0  8.4a
Insulin AUC (pmol/liter  min) 51,615.3  6,910.5 33,506  3,732a,b 37,731  4,380 40,050  4,680
HOMA index (mIU/liter/mg/dl) 16.1  2.1 12.6  1.1a,b 11.6  1.1 14.1  1.7
Insulin sensitivity index (mmol1/pmol1/liter) 16.3  3.5 19.6  2.7c 16.9  2.0 15.2  1.8
Serum triglycerides (mmol/liter) 1.2  0.1 1.08  0.1 1.2  0.1 1.3  0.1
Serum cholesterol (mmol/liter) 4.8  0.2 4.6  0.1 4.8  0.2 4.7  0.2
DHEAS (mol/liter) 5.4  0.6 5.8  0.7 6.3  0.6 6.8  0.5
Testosterone (nmol/liter) 2.4  0.3 2.1  0.2 2.8  0.2 2.5  0.2a
SHBG (nmol/liter) 36.8  4.3 40.8  3.3b 40.9  3.5 35.8  4.0a
FAI (U) 9.3  2.2 6.4  1.2b 8.5  1.6 9.8  2.0
a P  0.05 vs. baseline (by ANOVA).
b P  0.02 pioglitazone vs. placebo (by ANOVA).
c P  0.05 pioglitazone vs. placebo (by ANOVA).
J Clin Endocrinol Metab, April 2009, 94(4):1229–1235 jcem.endojournals.org 1231
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 04 February 2014. at 06:59 For personal use only. No other uses without permission. . All rights reserved.
tween serum visfatin concentration and any of the hormonal
parameters associated with PCOS.
RBP4
We found that serum RBP4 levels tended to decrease in re-
sponse to treatment with pioglitazone (P  0.06), whereas no
change was found in the placebo group (P 0.381; Fig. 1, E and
F). The change of RBP4 serum concentration did not reach sta-
tistical significance, perhaps due to the limited number of pa-
tients in our analysis. At baseline (all patients combined), RBP4
serumconcentrationswere positively associatedwith serumcon-
centrations of 17-OH progesterone (R  0.354; P  0.037),
DHEAS (R  0.347; P  0.041), and testosterone (R  0.466;
P 0.005). Because insulin is related to both RBP4 and steroid
hormones, potentially confounding effects of insulin were ad-
dressedbymultivariate regressionanalysis.However, significant
associations of RBP4 with testosterone (P  0.001), DHEAS
(P  0.008), and 17-OH progesterone (P  0.042) were main-
tained after adjustment for insulin. None of these parameters
correlated with the concentration of RBP4 after pioglitazone
treatment. The FAI correlated with serum RBP4 concentrations
(R  0.406; P  0.016), and this correlation remained present
after pioglitazone treatment (R  0.438; P  0.009). As dem-
onstrated previously, no changes in serum DHEAS and testos-
terone concentrations were found in response to pioglitazone
treatment in this cohort; however, treatmentwas associatedwith
an increase in SHBG, resulting in adecrease in theFAI (P0.05).
We therefore examined whether patients with low and high se-
rum RBP4 concentrations differed with regard to the phenotyp-
ical expression of PCOS. The study population was divided into
twogroupsusing themedian level of 22mg/dl as cutoff value.We
found that 17 patients with serumRBP4 concentrations ranging
from 15.2 – 21.6 mg/dl had lower hirsutism scores than 18 pa-
tients with serum RBP4 concentrations ranging from 22.1–31.6
mg/dl (P  0.038 before treatment; P  0.034 after treatment;
Fig. 2, A and B). Moreover, the patients with higher initial hir-
sutism scores had a more pronounced reduction in serum RBP4
concentrations in response topioglitazone treatment (R0.629;
P 0.009). Baseline serum FSH concentrations were negatively
correlated with RBP4 (R  0.334; P  0.050). However, the
FIG. 1. Adipokine serum concentrations before and after pioglitazone treatment. Diagrams depict the serum concentrations of the adipokines adiponectin (A and B),
visfatin (C and D), and RBP4 (E and F) in the treatment group and in patients receiving placebo. Paired t test was performed to compare adiponectin, visfatin, and RBP4
concentrations before and after pioglitazone treatment.
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response to the LHRH stimulation test was not related to serum
RBP4 concentrations at 20, 40, or 60 min. No correlation was
found between serum RBP4 and SHBG concentrations. Al-
though serum RBP4 levels tended to decrease in response to
pioglitazone treatment, we did not observe significant associa-
tions with parameters of impaired glucose metabolism such as
fasting glucose, response to oral glucose tolerance testing, and
baseline and end-of-treatment insulin. After adjustment for BMI
and high-density lipoprotein cholesterol, HOMA-IR as an indi-
cator of IR was weakly correlated to RBP4 (R  0.342; P 
0.049). End-of-treatment RBP4 was weakly linked to ovulation
rates (R  0.331; P  0.063).
Discussion
As conditions linked to IR like PCOS become increasingly com-
mon, it is an important agenda of research to elucidate the com-
plex pathophysiological interplay between excess adipose tissue,
IR, and endocrine changes. Furthermore, overweight and hir-
sutism along with impaired reproductive function may substan-
tially affect the quality of life (22). Over the past few years,
adipokines have emerged as an intensively studied group of se-
rumproteins andhavebeen identified as keyplayers inmediating
changes between adipocytes and organs affected in IR (20, 23).
A close relationship between IR and the PCOS has been firmly
established (24, 25). Moreover, distinct changes in steroid hor-
mone metabolism such as increased androgen and decreased
SHBGconcentrations are typical ofPCOS. It is therefore relevant
to investigate the contribution of various adipokines in facilitat-
ing such diverse pathophysiological alterations.
In our double-blind, randomized, placebo-controlled study,
we aimed at elucidating the potential roles of the recently iden-
tified adipokine RBP4 together with adiponectin and visfatin in
PCOS. Various studies have been performed investigating the
potential contribution of adipokines to the pathogenesis of
PCOS. Particularly the key adipokine leptin has been shown to
be involved in the pathogenesis of PCOS (26). Adiponectin has
been extensively investigated recently, and a role in mediating
insulin sensitivity in PCOSpatients has beenwell defined as is the
case for other conditions associated with IR or obesity (27–32).
Adiponectin affects glucose and lipid metabolism and displays
antiinflammatory properties (33). In line with previous investi-
gations (34), we found that the serum concentrations of adi-
ponectin rose in response to treatment with the peroxisome pro-
liferator-activated receptor (PPAR)- agonist pioglitazone.
Similarly, serumadiponectin concentrations correlatedwith sev-
eral markers of glucose metabolism in our patients, and an ame-
lioration of insulin sensitivity was observed along with higher
adiponectin concentrations after treatmentwith pioglitazone. In
our patients, HOMA-IR correlated with adiponectin only after
treatment with pioglitazone, but not at baseline. Our study co-
hort consisted of young PCOS patients with a relatively homog-
enous metabolic profile, including a low level of IR. We suggest
that small differences within the cohort at baseline account for
the fact that no association was detected between adiponectin
and HOMA-IR. After pioglitazone treatment, however, adi-
ponectin increased in the treatment group and remained un-
changed in the placebo group, which might explain why high
adiponectin was then linked to lower IR in the correlation anal-
ysis. A close relationship of adiponectin with markers of IR has
been conclusively demonstrated in several previous reports.
Thus, our results are in line with observations in similar patient
groups. Earlier studies identified adiponectin as a potential con-
tributor to IR in PCOSpatients but did not find associationswith
endocrine characteristics of PCOS. Likewise, we did not observe
associations between adiponectin and parameters of endocrine
abnormalities in our PCOS patients, except for a striking corre-
lation with the response to LHRH after pioglitazone treatment.
Romualdi et al. (35) treated PCOS women with pioglitazone 45
mg/d and obtained similar results. It has been demonstrated that
treatment of obesewomenwith insulin-sensitizing agents results in
a decrease of serum LH concentrations (36–38). Lowering of in-
sulin levels reduces pituitary LH secretion as evidenced by in vitro
studies in cultured rat pituitary cells (39, 40). Interestingly, we ob-
served a decrease of LH levels in the placebo group along with a
slight reduction of serum insulin levels, further supporting a link
between insulin and pituitary LH biosynthesis. Hence, our results
confirm that adiponectin is involved in IR in PCOS patients.
Previous studies demonstrated the presence of higher visfatin
serum levels in PCOS compared with healthy controls (41, 42).
In our design, we investigated changes in visfatin levels in the
serum of women with PCOS treated with pioglitazone. How-
ever, we did not detect any change of visfatin serum levels after
FIG. 2. Hirsutism scores at baseline (A) and after treatment (B) in patients with high vs. low RBP4 serum concentrations. Low, Patients with low RBP4 serum
concentrations (n  17); high, patients with high serum RBP4 concentrations (n  18). Values are depicted as means (horizontal lines), 25th and 75th percentiles
(boxes), and minimum/maximum ranges. Calculations for statistically significant differences between the groups were performed by ANOVA.
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treatment. Therefore, the role of visfatin in PCOS remains
unclear.
In contrast, our results suggest that the adipokine RBP4 may
be involved in endocrine perturbations characteristic of PCOS,
whereas few correlations of RBP4were foundwith the indices of
IR. The few relationships between RBP4 and IR have been as-
sessed differently in PCOSpatients. Although some investigators
found an association of RBP4 with IR or obesity (43), this was
not confirmed in another well-designed study (44). In addition,
in a study by Hahn et al. (45), RBP4 serum concentrations were
related to BMI or fat mass in PCOS patients and controls but
were not significantly elevated in PCOS per se. In contrast to our
investigation, study subjects were recruited according to less
stringent criteria (45), which would likely result in a broader
spectrum of PCOS and would therefore also include subjects
who could be regarded “closer to normal.” Moreover, the fact
that only a minority of our patients was diagnosed as insulin
resistant may explain the lack of an association between RBP4
and parameters of IR.
Tan et al. (46) showed that steroid hormones, particularly
17-OH-estradiol, were capable of inducing adipose tissue RBP4
biosynthesis, thereby demonstrating that altered expression of
steroid hormones may contribute to metabolic perturbations in
PCOS patients. In that study, RBP4 and 17-OH-estradiol serum
concentrations were compared between controls and PCOS pa-
tients. Although the number of patients in our cohort was small,
we similarly found a link between steroid hormone levels and
RBP4 among the group of patients with PCOS that remained
significant even after adjustment for insulin. This finding high-
lights that the relationship between RBP4 and steroid hormones
is notonlydifferentbetween controls andPCOSsubjects, but can
also be found across the spectrum of PCOSmanifestations. This
makes RBP4 an attractive target for further researchwith regard
to the pathophysiologicalmechanisms linking PCOS steroid per-
turbations and obesity/IR. It is noteworthy that treatment with
the PPAR- agonist pioglitazone appeared to lower RBP4 serum
concentrations (P0.06) and to improve IRbut left testosterone
and DHEAS levels unchanged.
Pioglitazone treatment abolished this relationship between
RBP4 and steroid hormones both in the treatment group and in
all patients combined. Thus, we demonstrate that high RBP4
levels are present in patients with high androgen serum concen-
trations. Pioglitazone treatment leaves androgen concentrations
unchanged but decreasesRBP4. Several indirect lines of evidence
may explain why the close relationship between RBP4 and ste-
roid hormones was no longer observed after pioglitazone treat-
ment. In cultured ovarian cells, pioglitazone influences ovarian
steroid hormone metabolism by up-regulation of progesterone
biosynthesis and inhibition of testosterone and estradiol pro-
duction via insulin-dependent and -independent pathways (47).
Glitazones contribute to ovarian insulin sensitization by up-reg-
ulation of insulin receptor and insulin receptor substrate-1. In-
sulin-independent effects of PPAR- agonists may be mediated
by influencing steroidogenic acute regulatory protein expression
(48). Additionally, pioglitazone is capable of inhibiting aro-
matase-mediated estrogenbiosynthesis fromtestosterone,which
would increase serum testosterone concentrations (49). Thus,
the multifaceted and partially opposing actions of glitazones on
steroid metabolism may explain why no change in androgen
concentrations was observed after the treatment period.
Moreover, we found that RBP4 levels were linked to hirsut-
ism scores in our patient cohort and that patients with lowRBP4
levels also had lower hirsutism scores, but that hirsutism scores
did not change after treatmentwith pioglitazone. Thus, our find-
ings reflect the potential of glitazones to reduce IR in PCOS
patients but questions the ability of glitazones to target some
clinical manifestations of steroid abnormalities in PCOS. Piogli-
tazone treatment enhanced ovulatory rates and resulted in an
increaseof SHBGlevels alongwithadecreaseof theFAI,whereas
no effect on androgens and Ferriman-Gallwey hirsutism scores
was noted in our patients. It is well established that current
treatment modalities are unlikely to show beneficial effects on
androgen levels and hirsutism within 3 months of treatment.
Thus, the observation time of our study group comprising
patients with pronounced endocrine abnormalities may have
been too short for assessing the effects of glitazones on all
endocrine abnormalities.
In summary, we confirm the potential benefit of pioglitazone
treatment in improving serumconcentrations of adiponectin and
RBP4 leading to amore insulin-sensitive profile in youngwomen
with PCOS. We describe an intriguing relationship of the re-
cently identified adipokine RBP4 with several androgens and
progesterone. The response to treatment with pioglitazone sug-
gests that steroid hormones have the potential to influence IR
through a modification of RBP4 expression. Molecular mecha-
nisms and clinical relevance of this relationship still need to be
elucidated.
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